Challenges and Recommendations for Obtaining Chemical  Structures of Industry-Provided Repurposing CandidatesChristopher S...
Why old drugs ? Why repurposing?                                            More cost effective R&D?                     ...
From data hoarding           Pharma company data   to open data             hoarding - to open data              (IMDB)   ...
“Off the Shelf R&D”              Rare diseases need cures       All pharmas have assets on shelf that       reached clinic...
Finding Promiscuous Old Drugs for New Uses                                                everolimus                      ...
Approximate small-molecule drug and        proto-drug numbers Historical development entry         ~35,000 Approached regu...
MRC/AstraZeneca: Mechanisms of          Disease Call assets                                                        Launche...
22 moleculesfromAstraZeneca
NCATS                                                 May 2012 the National                                               ...
Library of Industry Provided Reagents                            Consists of 58 ‘parked’                            therap...
It started with a blog!http://goo.gl/uTswV   Southan et al., DDT, 18: 58-70 (2013)
Pooling resourceshttp://goo.gl/FW6Bl                        http://goo.gl/NXPVs
Searching for one member of the NCATS listJNJ-39393406, using a standard Google search,provides >1000 hits (some are highl...
Patterns of information disclosures                    Southan et al., DDT, 18: 58-70 (2013)
Different forms of compoundsprovided by the analyses of Southan and Lipinski(protonation state and tautomerization).Found ...
Single stereocenter inversion differencedetected during the analyses of Southan andLipinski for GSK1004723.               ...
Repurposing by similarity to known drugs                     Southan et al., DDT, 18: 58-70 (2013)
Repurposing by similarity to known drugs                      Southan et al., DDT, 18: 58-70 (2013)
Cutting to the   chase   Several months led to   structures   12 of 22 MRC cpds   41 of 56 NCATS cpds   Also ran predictio...
Making molecules publicDrew molecules inMMDS appTweeted them with#drugrepurposing#oddtVisible anddownloadable inOpen DrugD...
Adding links to most similar targets in          CHEMBL using CDD                            Data currently in a          ...
ChallengesDespite the comprehensive interrogation of data sources, somerepresentations remain equivocalOrganizations alloc...
RecommendationsAuthors to ensure their drafted PubMed abstract encapsulates thecode name-to-structure mapping by having th...
Acknowledgments Chris Lipinski Dr Jeremy Yang and colleagues (University of New Mexico) for  kindly providing access to ...
You can find me @...                                      CDD Booth 205PAPER ID: 13433PAPER TITLE: “Dispensing processes p...
Upcoming SlideShare
Loading in...5
×

Challenges and recommendations for obtaining chemical structures of industry

641

Published on

There is an expanding interest in repurposing and repositioning of drugs as well as how in silico methods can assist these endeavors. Recent repurposing project tendering calls by the National Center for Advancing Translational Sciences (US) and the Medical Research Council (UK) have included compound information and pharmacological data. However none of the internal company development code names were assigned to chemical structures in the official documentation. This not only abrogates in silico analysis to support repurposing but consequently necessitates data gathering and curation to assign structures. We describe here the methods results and challenges associated with this, including the fact that ~40-50% of the code names remain completely blinded. In addition we describe the in silico predictions that are enabled once the structures are accessible. Consequently we suggest approaches to encourage earlier release of name to structure mappings into the public domain.

Published in: Technology, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
641
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
12
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Challenges and recommendations for obtaining chemical structures of industry

  1. 1. Challenges and Recommendations for Obtaining Chemical Structures of Industry-Provided Repurposing CandidatesChristopher Southan 1, Antony J. Williams2 and Sean Ekins3,4 1 TW2Informatics, Göteborg, Sweden 2 Royal Society of Chemistry, Wake Forest, NC. 3 Collaborations in Chemistry, Fuquay Varina, NC. 4Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, USA.
  2. 2. Why old drugs ? Why repurposing?  More cost effective R&D?  Repurposing/ repositioning - Quicker to bring to market?  Recent focus on neglected & rare diseases  Over 7000 diseases affecting less than 200,000  1000’s of diseases with no treatments  >300 orphan drugs approved since 1983Ekins S, Williams AJ, Krasowski MD and Freundlich JS, Drug Disc Today, 16: 298-310, 2011
  3. 3. From data hoarding Pharma company data to open data hoarding - to open data (IMDB) Me Linked Open data cloud 2011 (Wikipedia)
  4. 4. “Off the Shelf R&D” Rare diseases need cures All pharmas have assets on shelf that reached clinic Find new uses for these molecules Get to the patient faster
  5. 5. Finding Promiscuous Old Drugs for New Uses everolimus 5-fluorouracil ceftriaxoneCould In silico / in vitro repositioning find leads-drugs quicker?
  6. 6. Approximate small-molecule drug and proto-drug numbers Historical development entry ~35,000 Approached regulatory entry (INNs) ~7,000 Between clinical phases ~15,000 In active trials ~1,500 FDA approved ~1,400 INNs issued per year ~150 Discontinued (post approval) ~50 New approvals per year ~15
  7. 7. MRC/AstraZeneca: Mechanisms of Disease Call assets Launched Dec 2011http://goo.gl/R8trNhttp://www.mrc.ac.uk/Fundingopportunities/Calls/MoD/MRC008389
  8. 8. 22 moleculesfromAstraZeneca
  9. 9. NCATS May 2012 the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) launched the ‘Discovering New Therapeutic Uses for Existing Molecules’ program. http://goo.gl/FWchwhttp://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeutic-uses/directory.html
  10. 10. Library of Industry Provided Reagents Consists of 58 ‘parked’ therapeutic agents contributed by eight drug companies, To be evaluated by academics as a repurposing pilot effort funded by NCATSNo structures provided on website!
  11. 11. It started with a blog!http://goo.gl/uTswV Southan et al., DDT, 18: 58-70 (2013)
  12. 12. Pooling resourceshttp://goo.gl/FW6Bl http://goo.gl/NXPVs
  13. 13. Searching for one member of the NCATS listJNJ-39393406, using a standard Google search,provides >1000 hits (some are highlighted here)
  14. 14. Patterns of information disclosures Southan et al., DDT, 18: 58-70 (2013)
  15. 15. Different forms of compoundsprovided by the analyses of Southan and Lipinski(protonation state and tautomerization).Found by AJW - manual review of the ChemFOlderfile http://goo.gl/yIcVy Southan et al., DDT, 18: 58-70 (2013)
  16. 16. Single stereocenter inversion differencedetected during the analyses of Southan andLipinski for GSK1004723. Southan et al., DDT, 18: 58-70 (2013)
  17. 17. Repurposing by similarity to known drugs Southan et al., DDT, 18: 58-70 (2013)
  18. 18. Repurposing by similarity to known drugs Southan et al., DDT, 18: 58-70 (2013)
  19. 19. Cutting to the chase Several months led to structures 12 of 22 MRC cpds 41 of 56 NCATS cpds Also ran predictions with TB and malaria Bayesian models (data on request)Southan et al., DDT, 18: 58-70 (2013)
  20. 20. Making molecules publicDrew molecules inMMDS appTweeted them with#drugrepurposing#oddtVisible anddownloadable inOpen DrugDiscovery TeamsMobile app (free)Mol Informatics, 31: 585-597, 2012
  21. 21. Adding links to most similar targets in CHEMBL using CDD Data currently in a private vault Potential target inference by ligand similarity Will make public Validation
  22. 22. ChallengesDespite the comprehensive interrogation of data sources, somerepresentations remain equivocalOrganizations allocating the company codes have the primaryprovenance for the fidelity of the relationship between databaseelectronic structure representations and their own results in vitro, invivo and in the clinic.Avoid duplication of effort by othersCompanies interested in verifying or correcting our assignments,or even surfacing de novo their hitherto blinded mappings, arewelcome to contact us.
  23. 23. RecommendationsAuthors to ensure their drafted PubMed abstract encapsulates thecode name-to-structure mapping by having the code name andIUPAC juxtaposed in the abstract text (in the title is even better)Inclusion in the abstract of the Human Genome Organization(HUGO) Gene Nomenclature Committee (HGNC) gene symbol forthe primary target (or other major protein database identifier fornon-human targets)Before resource-intensive experimental testing it would thereforebe valuable to run a battery of in silico methods to predict,prospectively, potential new targets and new uses and reduce off-target or safety risksProvide repurposing opportunities that were not envisaged in theinitial proposal calls.
  24. 24. Acknowledgments Chris Lipinski Dr Jeremy Yang and colleagues (University of New Mexico) for kindly providing access to the Smartsfilter web application Alex Clark (MMI) Steve Carney & Reviewers at DDT Mike Travers Barry Bunin Disclaimer We accept no responsibility for the correctness of the structures
  25. 25. You can find me @... CDD Booth 205PAPER ID: 13433PAPER TITLE: “Dispensing processes profoundly impact biological assays and computational and statisticalanalyses”April 8th 8.35am Room 349PAPER ID: 14750PAPER TITLE: “Enhancing High Throughput Screening For Mycobacterium tuberculosis Drug DiscoveryUsing Bayesian Models”April 9th 1.30pm Room 353PAPER ID: 21524PAPER TITLE: “Navigating between patents, papers, abstracts and databases using public sources andtools”April 9th 3.50pm Room 350PAPER ID: 13358PAPER TITLE: “TB Mobile: Appifying Data on Anti-tuberculosis Molecule Targets”April 10th 8.30am Room 357PAPER ID: 13382PAPER TITLE: “Challenges and recommendations for obtaining chemical structures of industry-providedrepurposing candidates”April 10th 10.20am Room 350PAPER ID: 13438PAPER TITLE: “Dual-event machine learning models to accelerate drug discovery”April 10th 3.05 pm Room 350
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×